144 related articles for article (PubMed ID: 26548940)
21. Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database.
Moreira DM; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2010 Jan; 105(1):28-33. PubMed ID: 19522861
[TBL] [Abstract][Full Text] [Related]
22. Predicting survival of patients with node-positive prostate cancer following multimodal treatment.
Abdollah F; Karnes RJ; Suardi N; Cozzarini C; Gandaglia G; Fossati N; Bianchi M; Boorjian SA; Sun M; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol; 2014 Mar; 65(3):554-62. PubMed ID: 24094576
[TBL] [Abstract][Full Text] [Related]
23. Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy.
Eisenberg MS; Karnes RJ; Kaushik D; Rangel L; Bergstralh EJ; Boorjian SA
J Urol; 2013 Nov; 190(5):1735-41. PubMed ID: 23727312
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant radiotherapy following radical prostatectomy for prostate cancer.
Daly T; Hickey BE; Lehman M; Francis DP; See AM
Cochrane Database Syst Rev; 2011 Dec; (12):CD007234. PubMed ID: 22161411
[TBL] [Abstract][Full Text] [Related]
25. [Adjuvant vs. salvage radiotherapy after radical prostatectomy].
Bartkowiak D; Schrader AJ; Wiegel T
Aktuelle Urol; 2015 Jan; 46(1):52-8. PubMed ID: 25658231
[TBL] [Abstract][Full Text] [Related]
26. Radical prostatectomy for clinical T4 prostate cancer.
Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
[TBL] [Abstract][Full Text] [Related]
27. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
[TBL] [Abstract][Full Text] [Related]
28. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
[TBL] [Abstract][Full Text] [Related]
29. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.
Wiegel T; Bartkowiak D; Bottke D; Thamm R; Hinke A; Stöckle M; Rübe C; Semjonow A; Wirth M; Störkel S; Golz R; Engenhart-Cabillic R; Hofmann R; Feldmann HJ; Kälble T; Siegmann A; Hinkelbein W; Steiner U; Miller K
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):288-94. PubMed ID: 25445556
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant radiation with hormonal therapy is associated with improved survival in men with pathologically involved lymph nodes after radical surgery for prostate cancer.
Wong AT; Schwartz D; Osborn V; Safdieh J; Weiner J; Schreiber D
Urol Oncol; 2016 Dec; 34(12):529.e15-529.e20. PubMed ID: 27443637
[TBL] [Abstract][Full Text] [Related]
32. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
[TBL] [Abstract][Full Text] [Related]
33. Long-term oncological outcomes after laparoscopic radical prostatectomy.
Hruza M; Bermejo JL; Flinspach B; Schulze M; Teber D; Rumpelt HJ; Rassweiler JJ
BJU Int; 2013 Feb; 111(2):271-80. PubMed ID: 22757970
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
36. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
Zhou P; Chen MH; McLeod D; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Oct; 23(28):6992-8. PubMed ID: 16192586
[TBL] [Abstract][Full Text] [Related]
37. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
[TBL] [Abstract][Full Text] [Related]
38. Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer.
Kowalczyk KJ; Gu X; Nguyen PL; Lipsitz SR; Trinh QD; Lynch JH; Collins SP; Hu JC
Urol Oncol; 2014 Apr; 32(3):303-8. PubMed ID: 24321259
[TBL] [Abstract][Full Text] [Related]
39. Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty.
Kim SP; Tilburt JC; Karnes RJ; Ziegenfuss JY; Han LC; Shah ND; Frank I; Smaldone MC; Gross CP; Yu JB; Trinh QD; Sun M; O'Malley RL; Nguyen PL
Urology; 2013 Oct; 82(4):807-12. PubMed ID: 23910088
[TBL] [Abstract][Full Text] [Related]
40. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
